Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2

Clinical Cancer Research

Volumn 5, Issue 3, 1999, Pages 687-693

  Cabanes, Anna ^a   Even Chen, Simcha ^b   Zimberoff, Jacqueline ^a,c   Barenholz, Yechezkel ^b   Kedar, Eli ^c   Gabizon, Alberto ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c HEBREW UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DOXORUBICIN; INTERLEUKIN 2; LIPOSOME; MACROGOL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOKINE RELEASE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; IMMUNOMODULATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MODEL;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG CARRIERS; FEMALE; IMMUNOTHERAPY; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; INTERLEUKIN-2; LIPOSOMES; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; POLYETHYLENE GLYCOLS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0033030713     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Papahadjopoulos, D., Allen, T., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K. D., Woodle, M. C., Lasic, D. D., Redemann, C., and Martin, F. J. Sterically stabilized liposomes: improvements in pharmacokinetics and anti-tumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA, 88: 11460-11464, 1991.
2. Gabizon, A., Barenholz, Y., and Bialer, M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm. Res., 10: 703-708, 1993.
3. Working, P. K., Newman, M. S., Huang, S. K., Mayhew, E., Vaage, J., and Lasic, D. D. Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth liposomes (Doxil). J. Liposome Res., 4: 667-687, 1994.
4. Unezaki, S., Maruyama, K., Ishida, O., Suginaka, A., Hosoda, J., and Iwatsuru, M. Enhanced tumor targeting and improved anti-tumor activity of doxorubicin by long-circulating liposomes containing amphipathic poly(ethylene glycol). Int. J. Pharm. (Amst.), 126: 41-48, 1995.
5. Gabizon, A., Goren, D., Horowitz, A. T., Tzemach, D., Lossos, A., and Siegal, T. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv. Drug Delivery Rev., 24: 337-344, 1996.
6. Vaage, J., Donovan, D., Uster, P., and Working. P. Tumor uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. Br. J. Cancer, 75: 482-486, 1997.
7. Gabizon, A., and Barenholz, Y. Liposomal doxorubicin: from basics to clinical approval. In: A. Janoff (ed.), Liposomes: Rational Design, pp. 343-362. New York: Marcel Dekker, 1999.
8. Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., and Barenholz, Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res., 54: 987-992, 1994.
9. Ettinghausen, S. E., and Rosenberg, S. A. Immunotherapy of murine sarcomas using lymphokine-activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res., 46: 2784-2792, 1986.
10. Talmadge, J. E., Philips, H., Schindler, J., Tribble, H., and Pennington, R. Systematic preclinical study on the therapeutic properties of recombinant human recombinant interleukin-2 for the treatment of metastatic disease. Cancer Res., 47: 5725-5732, 1987.
11. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Malory, Y. L., Shibber, J. M., Shiloni, E., Vetto, J. T., Seipp, C. A., Simpson, C., and Reichert, C. M. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med., 313: 1485-1492, 1985.
12. Negrier, S., Mercatello, A., Bret, M., Theisse, P., Blay, J. Y., Corobnel, B., Merrouche, Y., Oskam, R., Franks, C. R., Clavel, M., Moskovtchenko, J. F., and Philip, T. Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma. Br. J. Cancer, 65: 723-726, 1992.
13. Rosenberg, S. A., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H., and White, D. E. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high dose bolus interleukin-2. J. Am. Med. Assoc., 271: 907-913, 1994.
14. Gautam, S. C., Chikkala, N. F., Ganapathi, R., and Hamilton, T. A. Combination therapy with Adriamycin and interleukin 2 augments immunity against murine renal cell carcinoma. Cancer Res., 51: 6133-6137, 1991.
15. LoRusso, P. M., Aukerman, S. L., Polin, L., Redman, B. G., Valdivieso, M., Biernat, L., and Corbett, T. H. Antitumor efficacy of interleukin-2 alone and in combination with Adriamycin and dacarbazine in murine solid tumor systems. Cancer Res., 50: 5876-5882, 1992.
16. Ehrke, M. J., Versovsek, S., Zaleskis, G., Ho, R. L. X., Ujhazy, P., Maccubbin, D. L., and Mihich, E. Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2. Cancer Immunol. Immunother., 42: 221-230, 1996.
17. Paciucci, P. A., Bekesi, G., Ryder, J. S., Odchimar, R., Chahinian, P. A., and Holland, J. F. Immunotherapy with IL2 by constant infusion and weekly doxorubicin. Am. J. Clin. Oncol., 14: 341-348, 1991.
18. Kedar, E., Rutkowski, Y., Braun, E., Emanuel, N., and Barenholz, Y. Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes. J. Immunother., 16: 47-59, 1994.
19. Kedar, E., Braun, E., Rutkowski, Y., Emanuel, N., and Barenholz, Y. Delivery of cytokines by liposomes. II. Interleukin-2 encapsulated in long-circulating sterically stabilized liposomes: immunomodulatory and anti-tumor activity in mice. J. Immunother., 16: 115-124, 1994.
20. Kedar, E., and Barenholz, Y. Delivery of cytokines by liposomes: a means of improving their immunomodulatory and antitumor activity. In: S. Chouaib (ed.), The Biotherapy of Cancers: From Immunotherapy to Gene Therapy, pp. 333-362. Paris: INSERM, 1998.
21. Kedar, E., Gur, H., Babai, I., Samira, S., Even-Chen, S., and Barenholz, Y. Delivery of cytokines by liposomes. IV. Hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes. J. Immunother., in press, 1999.
22. Haran, G., Cohen, R., Bar, L. K., and Barenholz, Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta, 1151: 201-215, 1993.
23. Koppenhagen, F. J., Visser, A. J., Herron, J. N., Storm, G., and Crommelin, D. J. Interaction of recombinant interleukin-2 with liposomal bilayers. J. Pharm. Sci., 87: 707-714, 1998.
24. Udenfriend, S., Stein, S., Bohlen, P., Dairman, W., Leimbruger, W., and Weigel, M. Fluorescamine: a reagent for assay of amino acids, peptides, proteins, and primary amines in the picomole range. Science (Washington DC), 178: 871-872, 1972.
25. Marks, T. A., Woodman, R. J., Geran, R. I., Billups, L. H., and Madison, R. M. Characterization and responsiveness of the Madison 109 lung carcinoma to various antitumor agents. Cancer Treat. Rep., 61: 1459-1470, 1977.
26. Gabizon, A., Chemla, M., Tzemach, D., Horowitz, A. T., and Goren, D. Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated antracyclines. J. Drug Targeting, 3: 391-398, 1996.
27. Gabizon, A., and Martin, F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumours. Drugs, 54 (Suppl. 4): 15-21, 1997.
28. Working, P. M., and Dayan, A. D. Pharmacological-toxicological expert report-CAELYX™ (Stealth® liposomal doxorubicin HC1). Hum. Exp. Toxicol., 15: 752-785, 1996.
29. Uziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Muggia, F. M., and Gabizon, A. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary Phase I studies. J. Clin. Oncol., 13: 1777-1785, 1995.
30. Kedar, E., and Klein, E. Cancer immunotherapy: are the results discouraging? Can they be improved? Adv. Cancer Res., 59: 245-322, 1992.
31. Anderson, P. M., Katsanis, E., Sencer, S. F., Hasz, D., Ochoa, A. C., and Bostrom, B. Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration. J. Immunother., 12: 19-31, 1992.
32. Anderson, P. M., and Sorenson, M. A. Effects of route and formulation on clinical pharmacokinetics of interleukin-2. Clin. Pharmacokinet., 27: 19-31, 1994.
33. Anderson, P. M., Katsanis, E., Leonard, A. S., Schow, D., Loeffler, C. M., Goldstein, M. B., and Ochoa, A. C. Increased local antitumor effects of interleukin 2 liposomes in mice with MCA sarcoma pulmonary metastases. Cancer Res., 50: 1853-1856, 1990.
34. Konno, H., Yamashita, A., Tadakuma, T., and Sakaguchi, S. Inhibition of growth of rat hepatoma by local injection of liposomes containing recombinant interleukin-2. Biotherapy, 3: 211-218, 1991.
35. Den Otter, W., De Groot, J. W., Bernsen, M. R., Heintz, P. M., Maas, R., Hordijk, G. J., Hill, F. G., Klein, W. R., Ruitenberg, E. J., and Rutten, V. P. Optimal regimes for local IL-2 tumor therapy. Int. J. Cancer, 66: 400-403, 1996.
36. Koppenhagen, F. J. Liposomes as delivery system for recombinant interleukin-2 in anticancer immunotherapy (thesis). Utrecht, The Netherlands: Utrecht University, 1997.
37. Edwards, R. P., Gooding, W., Lembersky, B. C., Colonello, K., Hammond, R., Paradise, C., Kowal, C. D., Kunschner, A. I., Baldisseri, M., Kirkwood, J. M., and Herberman, R. B. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: 24-hour versus 7-day infusion. J. Clin. Oncol., 15: 3399-2407, 1997.
38. Goey, S. H., Eggermont, A. M., Punt, C. J., Slingerland, R., Gratama, J. W., Oosterom, R., Oskam, R., Bolhuis, R. L., and Stoter, G. Intrapleural administration of interleukin 2 in pleural mesothelioma: a Phase I-II study. Br. J. Cancer, 72: 1283-1288, 1995.
39. Huland, E., Heinzer, H., Mir, T., and Huland, H. Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: six years of experience. Cancer J. Sci. Am., 3: 1-8, 1997.
40. Khanna, C., Anderson, P. M., Hasz, D. E., Katsanis, E., Neville, M., and Klausner, J. S. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer (Phila.), 79: 1409-1421, 1997.